Top 2 Health Care Stocks That May Collapse This Quarter
Top 2 Health Care Stocks That May Collapse This Quarter
As of Sept. 9, 2024, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年9月9日，醫療保健行業的兩隻股票可能會向將動量視爲交易決策關鍵標準的投資者發出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一個動量指標，它比較股票在價格上漲的日子裏的走強與價格下跌的日子的走強。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的數據，當相對強弱指數高於70時，資產通常被視爲超買。
Here's the latest list of major overbought players in this sector.
以下是該行業主要超買參與者的最新名單。
Terns Pharmaceuticals Inc (NASDAQ:TERN)
特恩斯製藥公司（納斯達克股票代碼：TERN）
- On Sept. 9, Terns Pharmaceuticals announced a top-line data from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of TERN-601 dosed once-daily in healthy adults with obesity or overweight.. The company's stock gained around 19% over the past month and has a 52-week high of $10.03.
- RSI Value: 73.09
- TERN Price Action: Shares of Terns Pharmaceuticals gained 4.7% to close at $7.81 on Friday.
- 9 月 9 日，Terns Pharmicals 公佈了其 1 期隨機、雙盲、安慰劑對照的單劑量和多遞增劑量試驗的主要數據，該試驗旨在評估肥胖或超重健康成年人每天給藥一次 TERN-601 的安全性、耐受性、藥代動力學和藥效學。該公司的股票在過去一個月中上漲了約19％，創下52周高點10.03美元。
- RSI 值：73.09
- TERN價格走勢：週五，Terns Pharmicals的股價上漲4.7％，收於7.81美元。
Immunovant Inc (NASDAQ:IMVT)
Immunovant Inc（納斯達克股票代碼：IMVT）
- On Sept. 9, Immunovant reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. "We are thrilled to share these updates today which we believe validate a large and important degree of unmet medical need in patients uncontrolled on ATDs and which we believe demonstrate strong response rates in this same population," said Pete Salzmann, M.D., chief executive officer of Immunovant. The company's stock gained around 17% over the past month and has a 52-week high of $45.58.
- RSI Value: 72.34
- IMVT Price Action: Shares of Immunovant surged 1.2% to close at $34.03 on Friday.
- 9月9日，Immunovant報告了巴托克利單抗治療格雷夫斯病的2a期試驗的陽性結果。Immunovant首席執行官Pete Salzmann萬.D. 表示：「我們很高興今天分享這些最新消息，我們認爲這些更新證實了ATD得不到控制的患者在很大程度上未得到滿足的醫療需求，而且我們認爲這些更新在同一人群中也顯示出很強的反應率。」該公司的股票在過去一個月中上漲了約17％，創下52周高點45.58美元。
- RSI 值：72.34
- iMVT價格走勢：週五，Immunovant的股價上漲了1.2％，收於34.03美元。
Read More:
閱讀更多：
- S&P 500 Records Largest Weekly Decline Since March 2023 As Nvidia, Google Tumble: Fear & Greed Index Moves To 'Fear' Zone
- 隨着英偉達和谷歌的暴跌，標普500指數創下自2023年3月以來的最大單週跌幅：恐懼與貪婪指數移至 「恐懼」 區域
譯文內容由第三人軟體翻譯。
